Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock

Critical Care Medicine

Volumn 36, Issue 2, 2008, Pages 448-454

  Stephens, Dianne P ^a   Thomas, Jane H ^a   Higgins, Alisa ^b   Bailey, Michael ^b   Anstey, Nicholas M ^a,c   Currie, Bart J ^a,c,d   Cheng, Allen C ^c,e  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Clinical trial; Granulocyte colony stimulating factor; Lenograstim; Septic shock

Indexed keywords

AZITHROMYCIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TROPONIN I;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LENGTH OF STAY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; TREATMENT OUTCOME;

EID: 38549139528     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0B013E318161E480     Document Type: Article

References (40)

1. Welte K, Gabrilove J, Bronchud MH, et al: Filgrastim (r-metHuG-CSF): The first 10 years. Blood 1996; 88:1907-1929
2. Bronchud MH, Potter MR, Morgenstern G, et al: In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 1988; 58:64-69
3. Weisbart RH, Golde DW: Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin North Am 1989; 3:401-409
4. Haberstroh J, Breuer H, Lucke I, et al: Effect of recombinant human granulocyte colony-stimulating factor on hemodynamic and cytokine response in a porcine model of Pseudomonas sepsis. Shock 1995; 4:216-224
5. O'Reilly M, Silver GM, Greenhalgh DG, et al: Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 1992; 33:679-682
6. Goya T, Torisu M, Doi F, et al: Effects of granulocyte colony stimulating factor and monobactam antibiotics (Aztreonam) on neutrophil functions in sepsis. Clin Immunol Immunopathol 1993; 69:278-284
7. Eichacker PQ, Waisman Y, Natanson C, et al: Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol 1994; 77:2366-2373
8. DeBoisblanc B, Guery B, Nelson S: Biological response modifiers and sepsis. In: Sepsis and Multiorgan Failure. Fein A, Abraham E, Balk R, et al (Eds). Baltimore, Williams and Wilkins, 1997
9. Marhoffer W, Stein M, Maeser E, et al: Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992; 15:256-260
10. Marhoffer W, Stein M, Schleinkofer L, et al: Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus. Diabetes Res Clin Pract 1993; 19:183-188
11. Salant DJ, Glover AM, Anderson R, et al: Depressed neutrophil chemotaxis in patients with chronic renal failure and after renal transplantation. J Lab Clin Med 1976; 88:536-545
12. Nelson S, Bagby G, Andresen J, et al: The effects of ethanol, tumor necrosis factor, and granulocyte colony-stimulating factor on lung antibacterial defenses. Adv Exp Med Biol 1991; 288:245-253
13. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
14. Weiss M, Moldawer LL, Schneider EM: Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 1999; 93:425-439
15. Nelson S, Bagby GJ: Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis. Clin Chest Med 1996; 17:319-332
16. McKenna P, Nelson S, Andresen J: Filgrastim (rHuG-CSF) enhances ciprofloxacin uptake and bactericidal activity of human neutrophils in vitro [abstract 535, American Thoracic Society meeting, May, 1996]. Am J Respir Crit Care Med 1996; 153
17. Nelson S, Belknap SM, Carlson RW, et al: A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia: CAP Study Group. J Infect Dis 1998; 178:1075-1080
18. Nelson S, Heyder AM, Stone J, et al: A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 2000; 182: 970-973
19. Mansmann G, Lammertink J, Hartmann P, et al: Ergebnisse einer randomisierten, plazebo-kontrollierten Studie zum Einsatz von Granulozyten-Kolonien-stimulierender Faktor (G-CSF) bei nosokomialer Pneumonie (NP) [Results of a randomised, placebo-controlled study on the use of Granulocyte colony stimulating factor in nosocomial pneumonia]. Pneumologie 2001, 55:S60
20. deBoisblanc BP, Mason CM, Andresen J, et al: Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia. Respir Med 1997; 91:387-394
21. Root RK, Lodato RF, Patrick W, et al: Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31:367-373
22. Stephens DP, Fisher DA, Currie BJ: An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 2002; 32:143-148
23. ACCP/SCCM: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874
24. Vincent J, de Mendonca A, Cantraine F, et al: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800
25. Myocardial infarction redefined: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000, 21:1502-1513
26. Azoulay E, Delclaux C: Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients? Intensive Care Med 2004; 30:10-17
27. Cheng AC, Stephens DP, Currie BJ: Granulocyte colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2003; 4:CD004400
28. Spencer JL, Silva DT, Snelling P, et al: An epidemic of renal failure among Australian Aboriginals. Med J Aust 1998; 168:537-541
29. Cheng AC, Stephens DP, Anstey NM, et al: Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004; 38:32-37
30. Cheng AC, Lowe M, Stephens DP, et al: Ethical problems of evaluating a new treatment for melioidosis. BMJ 2003; 327:1280-1282
31. Buentzel J, Kuettner K: Hepatic injury due to G-CSF application. Onkologie 1995; 18:54-56
32. Foster PF, Mital D, Sankary HN, et al: The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 1995; 59:1557-1563
33. Winston DJ, Foster PF, Somberg KA, et al: Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 1999; 68:1298-1304
34. Ammann P, Fehr T, Minder EI, et al: Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27:965-969
35. Fromm RE Jr: Cardiac troponins in the intensive care unit: common causes of increased levels and interpretation. Crit Care Med 2007, 35:584-588
36. Spies C, Haude V, Fitzner R, et al: Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998; 113:1055-1063
37. Ammann P, Maggiorini M, Bertel O, et al: Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003; 41:2004-2009
38. Finfer S, Bellomo R, Lipman J, et al: Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30:589-596
39. Vincent JL, Sakr Y, Sprung CL, et al: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34:344-353
40. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709